诺和锐30联合亚莫利治疗2型糖尿病临床观察

Insulin aspart 30 joint amaryl treatment in type 2 diabetic patients

目的观察42例单应用诺和锐30(2次/d,皮下注射)血糖控制不佳的2型糖尿患者,联合应用亚莫利治疗的临床效果。方法采用自身前后对照,临床观察42例2型糖尿病患者,应用诺和锐30(2次/d,皮下注射),疗程在>4～8周,诺和锐30用量已调至48～62u,血糖仍未达标(且有5例患者于午餐前及下午出现轻度低血糖症状)。联合口服亚莫利(2～4mg次/d)治疗2～4周,比较治疗前后空腹血糖(FPG)、餐后2h血糖(PPG)、糖化血红蛋白(HbA1c)水平、低血糖发生及胰岛素用量变化情况。结果诺和锐30联合亚莫利治疗后FPG、2hPG、HbA1C均有明显下降,FPG(P<0.05),2h PG(P<0.01,HbA1C(P<0.05),平均全日胰岛素用量较前减少12%,无低血糖发生。结论诺和锐30联合亚莫利治疗2型糖尿病与单用胰岛素治疗相比更能有效地使血糖平稳达标,胰岛素用量较前减少16%,无低血糖发生。

Objective To observe 42 cases of single application of insulin aspart 30（two times / day,subcutaneously） for poor glycemic control in type 2 diabetic patients,combined application of Amaryl treatment clinical effect.Methods before-after controlled,clinical observation of 42 cases of type 2 diabetes mellitus patients,application of insulin aspart 30（two times / day,subcutaneous injection）,the course of treatment in 4 to 8 weeks or more,insulin aspart 30 dosage has been raised to 48～62 u,glucose remains standard（and 5 patients were on lunch and afternoon mild hypoglycemia symptoms）.Combined oral Amaryl（2～4mg / day ） for 2 to 4 weeks,before and after the treatment,fasting blood glucose（FPG）,2 hour postprandial blood glucose（PPG）, glycosylated hemoglobin（HbA1c） level,hypoglycemia and insulin dosage changes.Results insulin aspart 30 joint Amaryl after treatment with FPG,2hPG and HbA1C were significantly decreased,FPG（P0.05）,2h PG（P0.01,HbA1C（P0.05）,the average daily insulin dosage is reduced 12%,without hypoglycemia.Conclusion insulin aspart 30 joint Amaryl type 2 diabetes treated with insulin alone in the treatment of more than can effectively make blood sugar stable standards,insulin dosage is reduced 16%,without hypoglycemia.